Gout
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!
Rheumatology Round-Up with Drs. Kavanaugh & Cush
The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020.
The Lancet TheLancet
4 years 7 months ago
Latebreaking at #ACR20—Febuxostat was non-inferior to allopurinol with regard to the occurrence of major cardiovascular outcomes in patients with gout: finding from FAST, multicentre, prospective, randomised, open-label, non-inferiority trial https://t.co/cpoNi7zjwi https://t.co/uQyeyepPmj
Febuxostat, a nonpurine xanthine oxidase inhibitor used in the treatment of chronic gout to lower serum urate levels, received bad press in 2019 after the US Food and Drug Administration (FDA) placed a black-box warning on the medication’s label suggesting that it increases the risk of cardiovascular (CV) death in patients with preexisting CV disease.
Dr. John Cush RheumNow
4 years 7 months ago
The folly of dietary restriction in contemporary gout? by @RichardPAConway
Dr. Conway discusses the abstracts presented at #ACR20
https://t.co/bJBKXKdftO https://t.co/Y5MXcNJQmS
How FAST can you go? Dr. Michael Pillinger
Dr. Pillinger weighs in with his view of the FAST trial (abstract L08) presented at ACR 2020.
Cardiovascular Safety for Feboxustat with Dr. Nicola Dalbeth
Auckland's Dr. Dalbeth examines the cardiovascular safety in the FAST trial of feboxustat (abstract L08) presented at the ACR 2020.
Mid-Meeting Recap: Gout
On Saturday, November 7th, Drs. Cush and Kavanaugh discuss gout studies presented at ACR 2020 with Dr. Michael Pillinger and Dr. Bella Mehta.
Olga Petryna DrPetryna
4 years 7 months ago
@RheumNow #ACR20 abs1921 single center baseline & follow-up PET/CT scan study in pts w/ refractory LVV-GCA on TCZ: while 83.33%pts achieved clincial remission only 10% experiences normalization of Total vascular score. https://t.co/sQK4L7Zu76
Dr. Ken Saag - RECIPE Study: MMF with Pegloticase
Dr. Jack Cush interviews Dr. Ken Saag about the benefits of adding mycophenolate to your pegloticase regimen in refractory gout patients.
k dao KDAO2011
4 years 7 months ago
The FAST trial had 33% of pts with CVD and pts w/class III/IV CHF were not allowed in this study (vs. CARES trial where all subjects had baseline CVD); I am still cautious prescribing febuxostat to pts who have severe CVD until we have more data. @RheumNow https://t.co/fJ9bLcXpR2
Dr. John Cush RheumNow
4 years 7 months ago
IN GOUT: CARES study said febuxostat increases CV risk; Todays FAST study says No incr CV risk w/ FEB. In your Gout pt w/ CV hx, would you use febuxostat? #ACR2020
David Liew drdavidliew
4 years 7 months ago
Following the results of the FAST trial, would you have any concerns about prescribing febuxostat if clinically indicated?
#ACR20 @RheumNow
Dr. John Cush RheumNow
4 years 7 months ago
GOUT: CARES study says febuxostat has high CV risk, new FAST study says no incr risk. Would you give FEB to a gout pt w/ CV risk?
Janet Pope Janetbirdope
4 years 7 months ago
Gout has more comorbidities than RA & PsA #1466 Half of respondents are correct @RheumNow @CRASCRRheum #ACR20 https://t.co/hjwYvCFJPk
Poster Hall